BofA SETTLES Case and 4 Mid-Week Stock Analyses to See Now
Orexigen Therapeutics, Inc. (NASDAQ:OREX): JMP Securities believes that the FDA’s approval of Vivus’s (NASDAQ:VVUS) weight loss drug, Orexigen(NASDAQ:OREX), is very likely. The firm reiterates an Outperform rating on Orexigen.
Don’t Miss: Vivus BREAKTHROUGH Opens Up the Obesity Market.
Intel Corporation (NASDAQ:INTC): After Intel Corporation lowered their full-year revenue guidance, ThinkEquity reduced its target on them. However, the firm still believes that they can grow. They maintain a Buy rating.
Amicus Therapeutics, Inc. (NASDAQ:FOLD): ThinkEquity believes that Amicus’s (NASDAQ:FOLD) expansion of their deal, with GlaxoSmithKline (NYSE:GSK), validates their technology and has granted them several concessions, including full U.S. rights in Fabry, as well as $18.6M in cash. The firm reiterates a $9 target and Buy rating on the company.
Kansas City Southern (NYSE:KSU): Even in their weakened position, Susquehanna recommends buying Kansas City Southern, given their secular growth. Shares are Positive rated.
Bank of America Corporation (NYSE:BAC): After Bank of America (NYSE:BAC) settled a mortgage putback case with bond insurer Syncora, BTIG Capital believes that they should also resolve their lawsuit with MBIA. If it is not settled, soon, the firm fears that the lawsuit may cause “an outsized risk,” for the bank.
Don’t Miss: Bank of America Earnings CHEAT SHEET.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.